A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still has several fundamental strong points, including an extensive pipeline of ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Goldman has recently reduced Moderna Inc (MRNA) stock to Neutral rating, as announced on January 29, 2025, according to Finviz. Earlier, on December 18, 2024, Argus had reduced the stock from a Buy to ...

Key Takeaways The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.